Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | SLC10A2 | Q12908 | 4/20 | 0.32 |
| ▸ | CTSD | P07339 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4732517 | 0.96 | NR1H4 (0.74) | NR1H4SLC10A2CTSD | |
| SCHEMBL25250178 | 0.95 | NR1H4 (0.79) | NR1H4KMT2AATMSLC10A2CTSD | |
| SCHEMBL4731985 | 0.95 | NR1H4 (0.79) | NR1H4KMT2AATMSLC10A2CTSD | |
| SCHEMBL5743635 | 0.93 | NR1H4 (0.83) | NR1H4KMT2AATMSLC10A2 | |
| SCHEMBL4617212 | 0.92 | NR1H4 (0.80) | NR1H4KMT2AATMSLC10A2CTSD | |
| SCHEMBL5273166 | 0.91 | NR1H4 (0.79) | NR1H4KMT2AATMSLC10A2CTSD | |
| SCHEMBL6049392 | 0.91 | NR1H4 (0.73) | NR1H4SLC10A2CTSD | |
| SCHEMBL920662 | 0.91 | NR1H4 (0.87) | NR1H4KMT2AATMSLC10A2 | |
| SCHEMBL19046392 | 0.91 | NR1H4 (0.87) | NR1H4KMT2AATMSLC10A2 | |
| SCHEMBL19807064 | 0.91 | NR1H4 (0.87) | NR1H4KMT2AATMSLC10A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2968230-A2 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PRIMARY SCLEROSING CHOLANGITIS AND INFLAMMATORY BOWEL DISEASE | Lumena Pharmaceuticals, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014144650-A2 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PRIMARY SCLEROSING CHOLANGITIS AND INFLAMMATORY BOWEL DISEASE | Lumena Pharmaceuticals, Inc. (US) | 2014-09-18 | — | — | WO | disclosed |
| EP-2575821-A2 | BILE ACID RECYCLING INHIBITORS AND SATIOGENS FOR TREATMENT OF DIABETES, OBESITY, AND INFLAMMATORY GASTROINTESTINAL CONDITIONS | Satiogen Pharmaceuticals, Inc. (US) | 2013-04-10 | — | — | EP | disclosed |
| WO-2011150286-A2 | BILE ACID RECYCLING INHIBITORS AND SATIOGENS FOR TREATMENT OF DIABETES, OBESITY, AND INFLAMMATORY GASTROINTESTINAL CONDITIONS | SATIOGEN PHARMACEUTICALS,INC. (US) | 2011-12-01 | — | — | WO | disclosed |
| EP-1879860-A2 | 1,4-DIPHENYL-3-HYDROXYALKYL-2-AZETIDINONE DERIVATIVES FOR TREATING HYPERCHOLESTROLEMIA | Microbia Inc. (US) | 2008-01-23 | — | — | EP | disclosed |
| WO-2006122186-A2 | 1,4-DIPHENYL-3-HYDROXYALKYL-2-AZETIDINONE DERIVATIVES FOR TREATING HYPERCHOLESTROLEMIA | MICROBIA, INC. (US) | 2006-11-16 | — | — | WO | disclosed |